HeartFlow/$HTFL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About HeartFlow
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.
Ticker
$HTFL
Sector
Primary listing
Employees
626
Headquarters
Website
HeartFlow Metrics
BasicAdvanced
$3.1B
-
-$15.63
-
-
Price and volume
Market cap
$3.1B
52-week high
$41.22
52-week low
$26.56
Average daily volume
328K
Financial strength
Current ratio
3.595
Quick ratio
3.411
Long term debt to equity
-158.171
Total debt to equity
-162.522
Interest coverage (TTM)
-2.81%
Profitability
EBITDA (TTM)
-60.657
Gross margin (TTM)
75.34%
Net profit margin (TTM)
-63.05%
Operating margin (TTM)
-41.88%
Effective tax rate (TTM)
-0.07%
Revenue per employee (TTM)
$240,000
Management effectiveness
Valuation
Price to revenue (TTM)
1.499
Price to book
-0.26
Price to tangible book (TTM)
-0.26
Price to free cash flow (TTM)
-3.274
Free cash flow yield (TTM)
-30.54%
Free cash flow per share (TTM)
-11.35
Growth
What the Analysts think about HeartFlow
Analyst ratings (Buy, Hold, Sell) for HeartFlow stock.
Bulls say / Bears say
Heartflow’s revenue surged 40% year-over-year to $43.4 million in Q2 2025, driven by a 47% increase in case volume and surpassing initial forecasts. (Reuters)
The company’s August 8, 2025 Nasdaq IPO raised $316.7 million at $19 per share, valuing Heartflow at $2.27 billion and strengthening its balance sheet to fund growth initiatives. (Reuters)
Gross margins remained robust at approximately 75.5% in Q2 2025, underscoring the high-margin economics of Heartflow’s software-driven diagnostic model. (Reuters)
In its Q1 2025 IPO filing, Heartflow reported a net loss of $32.3 million for the quarter ended March 31, up from $20.9 million a year earlier, underscoring persistent profitability challenges. (Reuters)
Operating expenses for Q2 2025 are anticipated at approximately $46.5 million, exceeding the $43.4 million in revenue and highlighting ongoing negative operating leverage and cash burn. (Reuters)
As of June 30, 2025, 98% of Heartflow’s revenue was derived from its FFRCT Analysis product, exposing the company to significant single-product concentration risk as Plaque Analysis commercialization remains nascent. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
HeartFlow Financial Performance
Revenues and expenses
HeartFlow Earnings Performance
Company profitability
HeartFlow News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for HeartFlow stock?
HeartFlow (HTFL) has a market cap of $3.1B as of November 02, 2025.
What is the P/E ratio for HeartFlow stock?
The price to earnings (P/E) ratio for HeartFlow (HTFL) stock is 0 as of November 02, 2025.
Does HeartFlow stock pay dividends?
No, HeartFlow (HTFL) stock does not pay dividends to its shareholders as of November 02, 2025.
When is the next HeartFlow dividend payment date?
HeartFlow (HTFL) stock does not pay dividends to its shareholders.
What is the beta indicator for HeartFlow?
HeartFlow (HTFL) does not currently have a Beta indicator.